Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)

Our objective was to identify drug interactions between ledipasvir (LDV) and sofosbuvir (SOF) against a genotype 1b replicon to determine optimal exposures for each agent that will maximize antiviral activity against susceptible and drug-resistant subpopulations. LDV and SOF were evaluated using a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Ashley N., Liu, Lin, Rodriquez, Jaime L., Zhao, Lisa, Schuster, Layla, Li, Eric, Wang, Gary P., Neely, Michael N., Yamada, Walter, Drusano, George L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663921/
https://www.ncbi.nlm.nih.gov/pubmed/29089577
http://dx.doi.org/10.1038/s41598-017-15007-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663921/
https://www.ncbi.nlm.nih.gov/pubmed/29089577
http://dx.doi.org/10.1038/s41598-017-15007-2

Ejemplares similares